信達生物(01801.HK)：Fortvita與Lostrancos訂立認購協議
格隆匯10月25日丨信達生物(01801.HK)公吿，於2024年10月25日，Fortvita與Lostrancos訂立認購協議，據此，Lostrancos有條件同意按認購價認購及購買，而Fortvita有條件同意按認購價發行及出售認購股份。認購價2050萬美元乃Fortvita與Lostrancos公平磋商達成。
於本公吿日期，Fortvita為公司的全資附屬公司。於交割後，Fortvita將由公司直接持有79.61%，並由Lostrancos直接持有20.39%。Fortvita仍將為公司的非全資附屬公司。
Fortvita為一家於開曼羣島註冊成立的有限公司，並於本公吿日期為公司的全資附屬公司。Fortvita集團主要致力於難治疾病先進療法在全球市場的研發，其管線主要處於早期階段。
建議認購事項反映了公司致力成為有競爭力的全球生物製藥公司的長期戰略目標。經過數年的發展，公司已建立起在中國市場領先的生物製藥平台並穩步擴展國內業務規模與提高經營效益，國內業務有望帶來日益穩健和可持續的回報。隨着公司在中國市場發展的同時，國際化業務擴張是公司另一主要戰略發展方向，而該業務目前尚處於發展早期階段，面臨諸多風險、挑戰和投資的不確定性。為綜合平衡國際化發展的資源需求和發展風險，Fortvita將作為公司推動國際業務的平台。此外，公司管理層主要成員承諾直接通過建議認購事項投資於Fortvita。
因此，建議認購事項是公司發展國際業務的良好起步，且公司管理層主要成員的直接投資，充分反映了彼等長期堅定發展海外業務的投入與決心，亦使彼等能夠在Fortvita的未來成長及發展中發揮更直接及積極的作用。
公司作為Fortvita的母公司將繼續領導及推進其發展，並繼續享有Fortvita帶來的潛在經濟利益，旨在為公司股東帶來長期的可持續回報。同時，建議認購事項的所得款項擬用於支持Fortvita的營運需要，從而加強Fortvita的財務狀況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
